PRICE. About us. Top co-authors. ABOUT. The intellectual property of Arrakis Therapeutics includes 4 registered patents primarily in the ' Organic Chemistry ' category, according to IPqwery. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Company Description: Arrakis Therapeutics, Inc. is located in Waltham, MA, United States and is part of the Scientific Research and Development Services Industry. Jennifer Petter, Ph.D., is a Founder & Chief Innovation Officer of Arrakis Therapeutics. We are looking for talented individuals to join the Arrakis team in the following positions: Research Associate/Senior Research Associate, Biophysics Waltham, MA. Our platforms enable us to identify therapeutic leads with exceptional speed and diversity. Monte Rosa's MGDs are rationally designed drug-like small molecules that create complementary surfaces between two proteins. It offers scientific platforms, such as TRYST, MARS, PEARL-Seq, to identify tractable RNA . The intellectual property of Arrakis Therapeutics includes 4 registered patents primarily in the ' Organic Chemistry ' category, according to IPqwery. Arrakis is building a proprietary pipeline of RNA-targeted small . Apply Now Job Salary Company Rating Description: Do you have the passion to join a group whose mission is to pioneer the discovery of a new class of medicines to treat diseases unaddressed by today's therapies? Leading the next generation of engineered therapeutics. Highly potent broadly neutralizing antibodies offer the best possibility to resolve the current COVID19 pandemic while also preparing for future outbreaks of related viruses. We're advancing a robust portfolio of therapeutic candidates bridging the innate and adaptive immune system. . Pioneering The Development of Novel Therapeutics Targeting Stress Support Pathways. Arrakis is building a proprietary pipeline of RNA-targeted small . jdoe@arrakistx.com) being used 94.9% of the time. A unique therapeutic approach. Creating A World Of Connection For People With Hearing And Balance Disorders. Associate Director/Director, Business & Corporate Development Waltham, MA. Arrakis Therapeutics 5.0 Associate Director/Director, Business & Corporate Development Waltham, MA $93K - $177K ( Glassdoor est.) Microbiome LBP Manufacturing. Creating advanced therapies is audacious. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care. Previously, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company . Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases . Our team embraces innovation and collaboration. Arrakis Therapeutics has 4 board members and advisors, including Colleen Cuffaro. Arrakis Therapeutics, Inc. has 75 total employees across all of its locations and generates $9.45 million in sales (USD). Arrakis Therapeutics Employee Reviews | Glassdoor 5.0 100 % Recommend to a Friend Choose a different language and keep reading other reviews. Arrakis Therapeutics's top competitors include ROPHIBIO, Reglagene, Exicure and Cytura Therapeutics. Contact Us; Privacy Policy Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. Our approach builds on the existing sophisticated drug discovery toolkit developed for . Richard Gaster Board Member Apr 2019. harnessing the potential of modern human genetics to treat disease. Choose the right Crunchbase solution for you . Division of Cancer Therapeutics and Division of Structural Biology; Yvette Newbatt. English (2 reviews) Other English (2 reviews) 5.0 Former Employee, more than 3 years Awesome team Nov 1, 2021 - Scientist in Boston, MA Recommend CEO Approval Business Outlook Pros Adagio Therapeutics Inc. Our mission is to provide an effective long-term solution for the global coronavirus challenge. the maze approach. Learn More. Arrakis Therapeutics Pharmaceutical Manufacturing Waltham, MA Beam Therapeutics Biotechnology Research . Arrakis Therapeutics has reported revenues of read more company news. April 11, 2022. Apr 23 2022. Press Release. 18 May 2022. Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation using our proprietary BEACON + (Blocking the Enzyme Activity Component of NAD +) platform. Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. Relay Therapeutics puts protein motion at the heart of drug discovery to dramatically expand therapeutic possibilities. At Arrakis, we dare to be extraordinary even when success isn't a guarantee. Skyhawk Therapeutics Europe GmbH Basel Technology Park Hochbergerstrasse 60C Basel 4057 Switzerland. Previously, Russ was Vice President of Drug Discovery at Avila Therapeutics and, upon the acquisition of Avila by Celgene in 2012, he became Celgene's Vice President of Chemistry, a position he held until leaving to found Arrakis in 2015. He joined Dynatrace as Chief Executive Officer in December 2021. I was in direct contact with HR and the hiring manager throughout the process. We are sharply focused on dry AMD which is a disease comprised of numerous genetic variants. 11.17. Prior to Dynatrace, he was President at Akamai Technologies and General Manager of . Helpful Report Work at Arrakis Therapeutics? Novel Therapeutics, Meaningful Connections. It may not be complete. Home; swiss-info@skyhawktx.com +41 (0) 61 638 23 50. Maze Therapeutics: translating genetic insights into therapeutic innovations. Stock Information. Pipeline. Read More. jane@arrakistx.com). May 05, 2022. Katrine Bosley Board Member 2019. Arrakis is developing a proprietary pipeline of RNA-targeted . VIEW ALL NEWS. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Additionally, Arrakis Therapeutics has registered 4 trademarks with the most popular class being ' Pharmaceutical, veterinary and sanitary products ', according to IPqwery. Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge, MA 02139 Phone: (857) 259-3840 Fax: (888) 459-2940 Company Description: Arrakis Therapeutics, Inc. is located in Waltham, MA, United States and is part of the Scientific Research and Development Services Industry. Nader Amin. Arrakis is developing a proprietary pipeline of RNA-targeted . Pinetree Therapeutics, Inc" has the MATESM platform technology to discover and develop a bispecific or multispecific antibody which potentially treats "so-called difficult-to-treat" solid cancers due to high mutation burden including undruggable genetic mutants. Read All. Fueling a new field in drug development. Additionally, Arrakis Therapeutics has registered 4 trademarks with the most popular class being ' Pharmaceutical, veterinary and sanitary products ', according to IPqwery. Arrakis Therapeutics 5.0 Scientist, Biophysics Waltham, MA $64K - $130K ( Glassdoor est.) The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare genetic diseases. April 8, 2022. More. Arrakis is the capstone of my career. Cambridge, MA 02139. info@relaytx.com (617) 370-8837. Learn About Our Science. Useful Links. Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. Arrakis Therapeutics Pharmaceuticals. Arrakis Therapeutics General Information. Virtual interviews were blocked out for an entire morning. BioXcel Therapeutics to Present at Three Upcoming Investor Conferences VIEW RELEASE. Russell Petter. LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create . The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. Get Verified Emails for 68 Arrakis Therapeutics Employees NEWS. | Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. CXOreach. Read about our scientists' publications in Science, Nature Biotechnology, at ASGCT and more. The other (weirdly) was our outside patent counsel. Search Scientist nmr spectroscopy jobs in Boston, MA with company ratings & salaries. You can compare up to 12 companies. It began with a zoom call only with the hiring manager followed by a seminar that I delivered to a broad audience of Arrakis . Developer of a drug discovery platform designed to find new points of therapeutic intervention. 18 open jobs for Scientist nmr spectroscopy in Boston. Arrakis Therapeutics has added information to its read more company news. The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare genetic . Start Your Free Trial . ABOUT US. BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights VIEW RELEASE. Please remove a company to add a new one. Kriya Therapeutics Salaries trends. Apply Now Job Salary Company Rating Description: Do you have the passion to join a group whose mission is to pioneer the discovery of a new class of medicines to treat diseases unaddressed by today's therapies? Our lead candidates are in the lead selection stage near the pre-clinical trial. Dr. Gilman is CEO of Arrakis and Chairman of the Board of Directors. Arrakis Therapeutics uses 2 email formats. Prior to that, I was CSO at RaNA Therapeutics (now Translate Bio), initially focused on targeting the function of long noncoding RNA in epigenetic regulation, and later transitioning to an mRNA therapeutics company. Arrakis Therapeutics has 4 board members and advisors, including Colleen Cuffaro. The interview process was with Arrakis Therapeutics was highly structured. Chief Executive Officer. Jennifer Petter Founder & CSO Executive Operations 1 email found View Katrine Bosley Chairman of the Board The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. The company was co-founded in 2015 by CEO Michael Gilman, a former Biogen executive who co-founded and led Padlock Therapeutics and Stromedix. Expansion Therapeutics News: Expansion Therapeutics Raises $80 Million Series B. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job that's . TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting. Transformative Oral Medicines for Severe RNA-Mediated Diseases. Close. Life at Decibel. Later that week in the office, Russ shared with Heather and me a proposed timetable for when he . . PLATFORM. We are pioneers in cell and gene therapy. 18 open jobs for Scientist nmr spectroscopy in Boston. Drawing upon our extensive experience in developing therapeutics for chronic liver diseases and viral infections, we are building a pipeline of potentially best-in-class drug candidates. Pipeline. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Waltham, MA $96K - $176K ( Glassdoor est.) We are leaping into the new possibilities of the RNA world, where every individual's contribution matters on our journey to help millions of patients. Project. One was Heather Lounsbury, our VP of Ops and Russ's long-time partner-in-crime at Avila and Celgene prior to Arrakis. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetic. Find high paying available jobs at Arrakis Therapeutics.For expert network information on Arrakis Therapeutics compensation and careers, use Ladders $100K + Club. Gemini Therapeutics is a precision medicine company focused on the development of new therapies through a deeper understanding of disease. Description. At the time of our dinner, only two people outside his personal world knew. Expansion Therapeutics has significantly expanded on scientific founder Matt Disney's . Other common formats are first (ex. Arrakis Therapeutics. We are genetic navigators, charting the complex maze of human genetics to create precision medicines to fight disease and help patients in need. Average salary for Transcode Therapeutics Software Engineer in Munich: 107,388. Learn how we are integrating artificial intelligence, chemistry, and biology to design . Department. Salaries posted anonymously by Kriya Therapeutics employees in North Carolina. Project. The Organization's Mission To re-architect drug discovery tools and methods to unlock previously inaccessible biology to create new medicines for millions of patients. Join Our Team. Arrakis Therapeutics 5.0 Associate Director/Principal Scientist, Machine Learning/A.I. About Us; Our Science; TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies. She is the author or co-author on over 50 papers and over 50 patents and/or . 1 salaries for 1 jobs at Kriya Therapeutics in North Carolina. The most common Arrakis Therapeutics email format is first_initial last (ex. Cyteir Therapeutics | 3,537 followers on LinkedIn. Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics JOIN THE EXPEDITION We are on a mission that takes fearlessness and resilience to pioneer new science, but we also make enjoying the journey as important as the destination.